GIM
TSHA icon

Granahan Investment Management’s Taysha Gene Therapies TSHA Stock Holding History

Granahan Investment Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.95M Buy
883,241
+179,270
+25% +$834K 0.19% 117
2025
Q4 		$3.87M Sell
703,971
-412,658
-37% -$2M 0.17% 126
2025
Q3 		$3.65M Buy
1,116,629
+158,136
+16% +$448K 0.15% 113
2025
Q2 		$2.21M Sell
958,493
-682,300
-42% -$1.48M 0.09% 132
2025
Q1 		$2.28M Buy
1,640,793
+4,412
+0.3% +$7.38K 0.11% 132
2024
Q4 		$2.83M Buy
1,636,381
+496,482
+44% +$1.03M 0.12% 138
2024
Q3 		$2.29M Buy
1,139,899
+330,208
+41% +$725K 0.09% 164
2024
Q2 		$1.81M Buy
+809,691
New +$2.36M 0.07% 160

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Granahan Investment Management's TSHA Position: Q1 2026 in Review

Granahan Investment Management increased its Taysha Gene Therapies (TSHA) stake by 25% in Q1 2026, buying an estimated $834K and bringing the position to 883,241 shares worth $3.95M. The position accounts for 0.19% of the portfolio, ranked #117.

Granahan Investment Management first reported a position in TSHA in Q2 2024 and has held it in 8 quarters since. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Granahan Investment Management held 883,241 shares of Taysha Gene Therapies worth $3.95M as of Q1 2026.
  • Granahan Investment Management bought 179,270 Taysha Gene Therapies shares in Q1 2026, an estimated $834K.
  • Taysha Gene Therapies made up 0.19% of Granahan Investment Management's portfolio in Q1 2026, its #117 holding.
  • Granahan Investment Management first reported a position in Taysha Gene Therapies in Q2 2024 and has held it in 8 quarters since.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Granahan Investment Management's 13F filing for Q1 2026, filed 15 May 2026.